News & Updates

Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).

Avelumab immunotherapy may perform poorly in advanced endometrial cancer (EC) patients with TP53 mutation but has positive effects in those with mutations of PTEN and ARID1A, suggest the results of the MITO END-3 trial.

Adherence to a healthy dietary pattern, such as the Mediterranean diet (MedDiet), may reduce the risk of gestational diabetes mellitus (GDM) but appears to increase exposure to harmful chemicals, according to a Singapore study presented at ADA 2024.